75. Cushing disease Clinical trials / Disease details
Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05361083 (ClinicalTrials.gov) | September 1, 2019 | 22/4/2022 | First-in-human Evaluation of [18F]CETO | Studies of 18F-CETO as a Tracer for Adrenal PET Diagnostics | Primary Aldosteronism Due to Aldosterone Producing Adenoma;Primary Aldosteronism Due to Nodular Hyperplasia;Adrenal Cushing Syndrome;Non-Secretory Adrenal Adenoma;Adrenocortical Carcinoma | Drug: F18CETO | Uppsala University | Uppsala University Hospital;British Medical Research Council | Completed | 18 Years | N/A | All | 20 | Early Phase 1 | Sweden |